Insider buying at ~$3.30 after a $15M offering at potentially dilutive terms suggests management sees value below recent capital raise price. Monitor for additional insider filings and next clinical catalyst (NEO212 Phase 2 initiation or FDA interaction for NEO100).
Price Chart
Executive Summary
CEO Amir Heshmatpour purchased 35,000 additional shares on September 15, 2026, for ~$115,400 at ~$3.30/share, extending a series of insider open-market purchases totaling ~$629,000 by two executives since positive Phase 2a NEO100 results were announced on August 12, 2026. The filing signals insider conviction following a $15M registered direct offering on September 9, 2026, but the company remains a clinical-stage biotech with no approved products and the Phase 2a study was a small single-arm trial.
Key Facts
- CEO purchased 35,000 shares on September 15, 2026, for ~$115,400 at ~$3.30/share
- Since August 12, 2026 Phase 2a results, CEO has purchased 111,000 shares for ~$418,700 at ~$3.77 avg
- CMO/CSO Thomas Chen purchased 49,016 shares for ~$210,000 since August 12
- Combined executive open-market purchases total 160,016 shares for ~$629,000
- CEO has invested >$1.5M of personal funds in NTHI over the past year
- Purchase follows a $15M registered direct offering announced September 9, 2026
- NEO100 Phase 2a study met primary endpoint: 6-month PFS 48.9% vs 20% benchmark (p=0.0047), median OS 26.09 months
- NEO212 completed Phase 1 dose escalation with recommended Phase 2 dose established
Financial Impact
CEO invested ~$115,400 in this purchase; cumulative executive purchases ~$629,000; CEO total personal investment >$1.5M over past year
Risk Factors
- Phase 2a was a single-arm, open-label study of 24 patients (not 28 planned), not powered as confirmatory
- Early-phase results may not replicate in larger controlled studies
- Company is clinical-stage with no approved products or revenue
- Recent $15M offering adds dilution; stock may face overhang from registered direct placement
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-010156 |
| Document: neonctechnologies_ex99-1.htm | 0001829126-26-010156 |
| Document: 0001829126-26-010156-index-headers.html | 0001829126-26-010156 |
| Document: 0001829126-26-010156-index.html | 0001829126-26-010156 |
| Document: 0001829126-26-010156.txt | 0001829126-26-010156 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $2.95 | awaiting T+60 | — | $3.24 (+9.83%) |
Oct 15, 2026 10d ago | 8-K | $2.70 | awaiting T+60 | — | $3.24 (+20.00%) |
Sep 18, 2026 5w ago | Insider Cluster | $3.33 | awaiting T+60 | — | $3.24 (−2.70%) |
Sep 17, 2026 5w ago | 8-K | $3.41 | awaiting T+60 | — | $3.24 (−4.99%) |
Sep 15, 2026 5w ago | Insider Cluster | $2.99 | awaiting T+60 | — | $3.24 (+8.36%) |
Sep 10, 2026 6w ago | 8-K | $3.66 | awaiting T+60 | — | $3.24 (+11.48%) |
Sep 10, 2026 6w ago | 424B5 | $3.66 | awaiting T+60 | — | $3.24 (+11.48%) |
Aug 20, 2026 9w ago | Insider Cluster | $4.68 | awaiting T+60 | — | $3.24 (−30.70%) |
Aug 18, 2026 9w ago | Insider Cluster | $5.53 | awaiting T+60 | — | $3.24 (−41.41%) |
Aug 12, 2026 10w ago | 8-K | $3.46 | awaiting T+60 | — | $3.24 (−6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers